XBIO Financial Statements

Balance sheet, income statement, cash flow, and dividends for Xenetic Biosciences Inc (XBIO).


$6.15M Market Cap.

As of 03/19/2025 5:00 PM ET (MRY) • Disclaimer

XBIO Market Cap. (MRY)


XBIO Shares Outstanding (MRY)


XBIO Assets (MRY)


Total Assets

$6.90M

Total Liabilities

$894.26K

Total Investments

$0

XBIO Income (MRY)


Revenue

$2.50M

Net Income

-$3.96M

Operating Expense

$6.70M

XBIO Cash Flow (MRY)


CF Operations

-$2.82M

CF Investing

$0

CF Financing

$0

XBIO Dividends (MRY)


Period

Dividends

Yield %

Growth %

Payout Ratio

Coverage Ratio

2024

$0

0%

0%

0%

-

2023

$0

0%

0%

0%

-

2022

$0

0%

0%

0%

-

2021

$0

0%

0%

0%

-

2020

$0

0%

-

0%

-

XBIO Balance Sheet (MRY)


Metric

2024

2023

2022

2021

Total Assets

$6,901,443 (-34.92%)

$10,605,226 (-27.96%)

$14,720,290 (-25.71%)

$19,815,360 (50.35%)

Assets Current

$6,587,522 (-31.29%)

$9,586,874 (-29.78%)

$13,653,359 (-27.08%)

$18,723,429 (51.37%)

Assets Non-Current

$313,921 (-69.17%)

$1,018,352 (-4.55%)

$1,066,931 (-2.29%)

$1,091,931 (34.81%)

Goodwill & Intangible Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Shareholders Equity

$6,007,180 (-38.67%)

$9,795,641 (-28.22%)

$13,647,134 (-25.81%)

$18,394,257 (50.58%)

Property Plant & Equipment Net

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Cash & Equivalents

$6,165,568 (-31.36%)

$8,983,046 (-31.41%)

$13,097,265 (-28.21%)

$18,244,030 (58.26%)

Accumulated Other Comprehensive Income

$253,734 (0.00%)

$253,734 (0.00%)

$253,734 (0.00%)

$253,734 (0.00%)

Deferred Revenue

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Investments

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Investments Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Investments Non-Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Inventory

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Trade & Non-Trade Receivables

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Trade & Non-Trade Payables

$283,615 (17.76%)

$240,832 (-16.19%)

$287,360 (-20.72%)

$362,470 (10.71%)

Accumulated Retained Earnings (Deficit)

-$197,194,471 (-2.05%)

-$193,234,196 (-2.19%)

-$189,099,618 (-3.59%)

-$182,547,265 (-3.19%)

Tax Assets

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Tax Liabilities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Debt

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Debt Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Debt Non-Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Total Liabilities

$894,263 (10.46%)

$809,585 (-24.56%)

$1,073,156 (-24.48%)

$1,421,103 (47.42%)

Liabilities Current

$894,263 (10.46%)

$809,585 (-24.56%)

$1,073,156 (-24.48%)

$1,421,103 (51.68%)

Liabilities Non-Current

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

XBIO Income Statement (MRY)


Metric

2024

2023

2022

2021

Revenues

$2,500,284 (-1.56%)

$2,539,986 (48.80%)

$1,706,925 (47.06%)

$1,160,692 (165.64%)

Cost of Revenue

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Selling General & Administrative Expense

$3,416,380 (-4.06%)

$3,560,936 (-2.55%)

$3,653,999 (-2.40%)

$3,743,972 (10.11%)

Research & Development Expense

$3,288,332 (-5.91%)

$3,494,765 (-26.75%)

$4,770,834 (50.81%)

$3,163,485 (82.71%)

Operating Expenses

$6,704,712 (-4.97%)

$7,055,701 (-16.25%)

$8,424,833 (21.97%)

$6,907,457 (-51.95%)

Interest Expense

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Income Tax Expense

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Loss Income from Discontinued Operations

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Consolidated Income

-$3,960,275 (4.22%)

-$4,134,578 (36.90%)

-$6,552,353 (-16.07%)

-$5,645,179 (48.18%)

Net Income to Non-Controlling Interests

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income

-$3,960,275 (4.22%)

-$4,134,578 (36.90%)

-$6,552,353 (-16.07%)

-$5,645,179 (48.18%)

Preferred Dividends Income Statement Impact

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Net Income Common Stock

-$3,960,275 (4.22%)

-$4,134,578 (36.90%)

-$6,552,353 (-16.07%)

-$5,645,179 (48.18%)

Weighted Average Shares

$1,541,339 (0.86%)

$1,528,210 (7.44%)

$1,422,443 (38.38%)

$1,027,941 (60.81%)

Weighted Average Shares Diluted

$1,541,339 (0.86%)

$1,528,210 (7.44%)

$1,422,443 (38.38%)

$1,027,941 (60.81%)

Earning Before Interest & Taxes (EBIT)

-$3,960,275 (4.22%)

-$4,134,578 (36.90%)

-$6,552,353 (-16.07%)

-$5,645,179 (59.13%)

Gross Profit

$2,500,284 (-1.56%)

$2,539,986 (48.80%)

$1,706,925 (47.06%)

$1,160,692 (165.64%)

Operating Income

-$4,204,428 (6.89%)

-$4,515,715 (32.78%)

-$6,717,908 (-16.90%)

-$5,746,765 (58.77%)

XBIO Cash Flow Statement (MRY)


Metric

2024

2023

2022

2021

Net Cash Flow from Investing

$0 (0%)

$0 (0%)

-$500,000 (0%)

$0 (0%)

Net Cash Flow from Financing

$0 (0%)

$0 (0%)

$0 (0%)

$11,454,545 (111.07%)

Net Cash Flow from Operations

-$2,817,478 (31.52%)

-$4,114,219 (11.46%)

-$4,646,765 (1.93%)

-$4,738,067 (-11.03%)

Net Cash Flow / Change in Cash & Cash Equivalents

-$2,817,478 (31.52%)

-$4,114,219 (20.06%)

-$5,146,765 (-176.63%)

$6,716,478 (479.19%)

Net Cash Flow - Business Acquisitions and Disposals

$0 (0%)

$0 (0%)

-$500,000 (0%)

$0 (0%)

Net Cash Flow - Investment Acquisitions and Disposals

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Capital Expenditure

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Issuance (Repayment) of Debt Securities

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Issuance (Purchase) of Equity Shares

$0 (0%)

$0 (0%)

$0 (0%)

$11,454,545 (111.07%)

Payment of Dividends & Other Cash Distributions

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Effect of Exchange Rate Changes on Cash

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Share Based Compensation

$171,814 (-39.31%)

$283,085 (-44.65%)

$511,480 (24.62%)

$410,437 (-12.47%)

Depreciation Amortization & Accretion

$0 (0%)

$0 (0%)

$27,043 (-23.78%)

$35,482 (23.04%)

XBIO Financial Metrics (MRY)


Metric

2024

2023

2022

2021

Gross Margin

100.00% (0.00%)

100.00% (0.00%)

100.00% (0.00%)

100.00% (0.00%)

Profit Margin

-158.40% (2.70%)

-162.80% (57.59%)

-383.90% (21.07%)

-486.40% (80.49%)

EBITDA Margin

-158.40% (2.70%)

-162.80% (57.42%)

-382.30% (20.90%)

-483.30% (84.68%)

Return on Average Equity (ROAE)

-54.30% (-49.18%)

-36.40% (16.32%)

-43.50% (-14.47%)

-38.00% (54.92%)

Return on Average Assets (ROAA)

-47.50% (-40.95%)

-33.70% (16.79%)

-40.50% (-14.41%)

-35.40% (50.00%)

Return on Sales (ROS)

-158.40% (2.70%)

-162.80% (57.59%)

-383.90% (21.07%)

-486.40% (84.61%)

Return on Invested Capital (ROIC)

-1523.70% (-263.56%)

-419.10% (64.03%)

-1165.20% (-15.69%)

-1007.20% (44.53%)

Dividend Yield

0% (0%)

0% (0%)

0% (0%)

0% (0%)

Price to Earnings Ratio (P/E)

-1.55 (-22.00%)

-1.27 (-105.32%)

-0.62 (73.56%)

-2.35 (-95.42%)

Price to Sales Ratio (P/S)

2.46 (18.50%)

2.08 (-12.63%)

2.38 (-79.20%)

11.43 (-61.72%)

Price to Book Ratio (P/B)

1.02 (88.58%)

0.54 (71.29%)

0.32 (-66.24%)

0.94 (-10.66%)

Debt to Equity Ratio (D/E)

0.15 (79.52%)

0.08 (5.06%)

0.08 (2.60%)

0.08 (-2.53%)

Earnings Per Share (EPS)

-2.57 (5.17%)

-2.71 (41.09%)

-4.6 (16.36%)

-5.5 (67.65%)

Sales Per Share (SPS)

1.62 (-2.41%)

1.66 (38.50%)

1.2 (6.29%)

1.13 (65.06%)

Free Cash Flow Per Share (FCFPS)

-1.83 (32.10%)

-2.69 (17.60%)

-3.27 (29.12%)

-4.61 (30.95%)

Book Value Per Share (BVPS)

3.9 (-39.20%)

6.41 (-33.19%)

9.59 (-46.38%)

17.89 (-6.36%)

Tangible Assets Book Value Per Share (TABVPS)

4.48 (-35.48%)

6.94 (-32.94%)

10.35 (-46.31%)

19.28 (-6.50%)

Enterprise Value Over EBIT (EV/EBIT)

0 (0%)

1 (0.00%)

1 (0%)

0 (0%)

Enterprise Value Over EBITDA (EV/EBITDA)

0.17 (-83.97%)

1.08 (-26.10%)

1.46 (236.41%)

0.43 (203.33%)

Asset Turnover

0.3 (44.93%)

0.21 (97.14%)

0.1 (43.84%)

0.07 (160.71%)

Current Ratio

7.37 (-37.80%)

11.84 (-6.92%)

12.72 (-3.43%)

13.18 (-0.20%)

Dividends

$0 (0%)

$0 (0%)

$0 (0%)

$0 (0%)

Free Cash Flow (FCF)

-$2,817,478 (31.52%)

-$4,114,219 (11.46%)

-$4,646,765 (1.93%)

-$4,738,067 (-11.03%)

Enterprise Value (EV)

-$686,425 (84.61%)

-$4,460,559 (53.17%)

-$9,524,175 (-291.58%)

-$2,432,237 (-142.01%)

Earnings Before Tax (EBT)

-$3,960,275 (4.22%)

-$4,134,578 (36.90%)

-$6,552,353 (-16.07%)

-$5,645,179 (59.13%)

Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)

-$3,960,275 (4.22%)

-$4,134,578 (36.64%)

-$6,525,310 (-16.32%)

-$5,609,697 (59.30%)

Invested Capital

-$158,388 (-119.49%)

$812,595 (47.78%)

$549,869 (266.03%)

$150,227 (-78.99%)

Working Capital

$5,693,259 (-35.14%)

$8,777,289 (-30.23%)

$12,580,203 (-27.29%)

$17,302,326 (51.34%)

Tangible Asset Value

$6,901,443 (-34.92%)

$10,605,226 (-27.96%)

$14,720,290 (-25.71%)

$19,815,360 (50.35%)

Market Capitalization

$6,153,135 (15.76%)

$5,315,514 (22.93%)

$4,323,997 (-74.96%)

$17,270,492 (34.46%)

Average Equity

$7,291,776 (-35.79%)

$11,356,375 (-24.64%)

$15,069,641 (1.39%)

$14,863,284 (15.04%)

Average Assets

$8,343,717 (-31.93%)

$12,257,816 (-24.27%)

$16,186,257 (1.52%)

$15,944,416 (3.59%)

Invested Capital Average

$259,919 (-73.65%)

$986,462 (75.42%)

$562,337 (0.33%)

$560,496 (-26.31%)

Shares

1,542,139 (0.09%)

1,540,684 (1.58%)

1,516,660 (13.29%)

1,338,798 (112.63%)